Indonesia vs Syria: Access to anti-retroviral drugs, female (%)
Indonesia
36.0%
in 2024
Syria
41.0%
in 2024
Indonesia rank
130th
Syria rank
127th
Access to anti-retroviral drugs, female (%) over time
- Indonesia
- Syria
How they compare
Syria currently reports 41.0% against 36.0% in Indonesia, a difference of 5.0%.
That makes Syria's figure about 1.1 times Indonesia's.
Across all 25 years both countries report, Syria has been ahead every year.
Indonesia ranks 130th and Syria ranks 127th of 141 countries.
Syria has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Indonesia | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.3% | 5.4% | 4.1% | Syria |
| 2010s | 12.9% | 26.9% | 14.0% | Syria |
| 2020s | 28.8% | 41.4% | 12.6% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Indonesia or Syria?
- Syria, at 41.0% against 36.0% in Indonesia as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Indonesia and Syria?
- 5.0%, with Syria ahead.
- How many years of comparable data are there for Indonesia and Syria?
- 25 years are reported by both, from 2000 to 2024.
- How do Indonesia and Syria rank globally for access to anti-retroviral drugs, female?
- Indonesia ranks 130th and Syria ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.